Where to Run a First-in-Human Study: US vs Canada vs Latin America, for Drugs and Devices (2026)

Where to run a first-in-human study: FDA IND/IDE and early feasibility studies, Health Canada CTA and ITA, Latin American regulators, review clocks with sources, and FDA acceptance of non-US data.

By Julio G. Martinez-Clark

CEO, bioaccess®

General information, not legal or regulatory advice. Review clocks are cited to the regulation or the regulator’s own guidance. Durations marked “bioaccess® experience” are planning estimates from our recent study timelines, not legal deadlines or guarantees. bioaccess® runs studies in all three regions, so this guide sets out the trade-offs rather than a single answer. Sources last checked: 29 October 2026.

In this guide: The short answer · Review clocks at a glance · Side-by-side comparison · United States · Canada · Latin America · Will FDA accept the data? · Decision guide · Hybrid plans · Questions to answer · Glossary · FAQ

The short answer

There is no single best region. The right choice depends on what the first study has to do for your program.

  • The United States fits when you want FDA to shape the study with you from the start, when US investigators matter for the next study, or when investors want US data. FDA’s review clock is 30 days for both an IND (drugs) and an IDE (devices). The time usually goes into the pre-submission work, institutional review and contracts around it.
  • Canada fits drug studies that want a 30-day default review (the trial is authorized if Health Canada does not object within 30 days), and device studies that can work with a 30-day review target, where the authorization for Class III and IV devices can be issued before ethics approval. Canada is also on FDA’s lists of countries with simplified export of investigational products.
  • Latin America fits when activation speed, patient access and cost are the binding constraints, and when the study is designed from day one so FDA can accept the data. The regulator clock and review order vary by country: from parallel ethics and regulator review timed to each committee’s meeting schedule (Panama), to several months for drug trials where the regulator clock is long (Brazil: ANVISA 90 business days) or starts after ethics (Colombia: INVIMA 60 business days).

Many programs use more than one region in sequence. The data rules below decide whether that works.

Review clocks at a glance

First-in-human regulator review clocks: US, Canada and Latin AmericaUS IND and IDE 30 days; Canada CTA 30-day default and ITA 30-day target; Panama about 4 weeks in parallel; Peru and Mexico about 6 weeks; Chile 45 days; Argentina about 6 to 9 weeks; Colombia first response about 12 weeks after ethics; Brazil about 18 weeks for drug dossiers.0 d30 d60 d90 d120 dUS IND (drugs)30 daysUS IDE (devices)30 daysCanada CTA (drugs)30-day defaultCanada ITA (devices)30-day targetPanama ethics + DNFDethics ≤20 bd + DNFD 15 bd, parallelPeru INSup to 30 working daysMexico COFEPRIS30 business days (guidance: calendar)Chile ISP (drugs)45-day term (unit: confirm)Argentina ANMAT (drugs)20+10 or 35+10 business daysColombia INVIMA (drugs)first response, 60 business days after ethicsBrazil ANVISA (drugs)90 business daysBlue: US. Green: Canada. Orange: Latin America. Panama includes its parallel ethics review; elsewhere ethics, contracts and import come on top.
Published review milestones with different start and end points, approximate calendar days (business days × 7/5). Not approval or time to first patient.

The chart shows different published review milestones, not comparable approval or activation durations: the IND clock starts at FDA receipt, the CTA at receipt of a complete application, the ITA at the start of screening, and Colombia’s is a first response after ethics. Panama includes ethics review (up to 20 business days, 10 expedited, or 30 in total for full-committee review). It is not the time to first patient. Business days are converted to calendar days at about 7 calendar days per 5 business days, before holidays.

Side by side: US, Canada and Latin America

Question United States Canada Latin America
Drug application IND to FDA Clinical Trial Application (CTA) to Health Canada National regulator application; varies by country
Device application IDE to FDA for significant-risk devices; non-significant-risk studies follow abbreviated IDE requirements with IRB approval Investigational Testing Authorization (ITA) for unlicensed Class II, III and IV devices; none for Class I Varies by country; confirm with us
Regulator clock IND takes effect after 30 days unless FDA places a clinical hold; an IDE study may begin after 30 days unless FDA objects (21 CFR 312.40; 21 CFR 812.30) CTA: 30-day default; ITA: 30-day target (CTA guidance; ITA guidance) About 4 weeks (Panama) to about 4 months (Brazil, drug dossiers); see the table below
What happens if the regulator says nothing IND takes effect after 30 days unless FDA places a clinical hold CTA: authorized if no objection within 30 days. ITA: no automatic authorization Depends on the country
Ethics review IRB at each site, or a central IRB Research Ethics Board (REB) per site Ethics committee per site or national committee; order varies
Ethics and regulator in parallel? Yes; IRB and FDA run separately Yes. For Class III and IV devices, the ITA letter can issue before REB approval Parallel in some countries (Panama; El Salvador (bioaccess® experience); Brazil submissions); sequential in others
Local presence needed FDA states that the sponsor of an IDE must be located in the US CTA attestation by a senior medical or scientific officer residing in Canada Varies by country; an importer of record is needed for the product. Confirm with us
Regulator fee Confirm with us CTAs and ITAs carry no Health Canada fee Varies; confirm with us
Labels US investigational labeling Drugs and devices: investigational statements in English and French Local-language labels in several countries (for example Spanish in Panama and Chile)
Export from the US Not needed Simplified: Canada is on FDA’s tier-one list for devices and on the listed countries in 21 CFR 312.110(b) for drugs Devices need FDA export approval under 801(e)(2); drugs ship under an IND in effect or, subject to its conditions, an export certification (21 CFR 312.110)
FDA use of the data Collected under the IND or IDE Foreign data: 312.120 (drug studies not conducted under an IND) and 812.28 (devices) Same as Canada

United States: IND, IDE and early feasibility studies

Drugs. An IND goes into effect 30 days after FDA receives it, unless FDA places the study on clinical hold, or earlier if FDA says so (21 CFR 312.40). FDA offers pre-IND meetings before the filing.

Devices. For a significant-risk device, the study can begin 30 days after FDA receives the IDE unless FDA objects, or when FDA approves it by order. FDA can approve, approve with modifications, or disapprove (21 CFR 812.30). Non-significant-risk device studies follow abbreviated requirements with IRB approval (21 CFR 812.2(b)). See IDE vs IND, what to send in a Q-Submission and IDE steps after you submit.

Early feasibility studies (EFS). An EFS is a small, early device study, typically before the design is final, used to check the concept and guide changes. FDA’s EFS Program offers interactive review, help from an EFS representative, potentially less non-clinical data when clinical risk mitigations are in place, and faster ways to change the device or protocol. FDA recommends a Pre-Submission before the IDE (FDA EFS Program; 2013 guidance on IDEs for early feasibility studies, including certain first-in-human studies).

Where the US time goes. The 30-day clock is often not the longest step. Pre-submission meetings, approval-with-modifications rounds, institutional review, hospital contracts and clinical-trial insurance add the time. Across regions, an industry benchmark found an average of 31.4 weeks from site identification to completed start-up, with repeat sites 9.9 weeks faster (Tufts CSDD, 2018).

Canada: CTA and ITA

Drugs (CTA). A sponsor needs a Clinical Trial Application to sell or import a drug for a phase I to III trial. Health Canada has 30 days from receipt of a complete application to object; without an objection the trial is authorized, and Health Canada typically issues a No Objection Letter. Answers to questions during review are due within 2 calendar days (CTA guidance).

The 7-day review is narrower than many sources suggest. Health Canada’s 7-day administrative target applies only to comparative bioavailability studies of pharmaceuticals: single dose, healthy adults, a reference product marketed in Canada, the US or a few other listed countries, and a study dose no higher than the reference product’s labeled maximum. It does not apply to biologics, cell or gene therapies, or to other studies such as first-in-human studies of a new drug, which follow the 30-day default (CTA guidance, 2.3.3; performance standards).

Devices (ITA). Unlicensed Class II, III and IV devices need an Investigational Testing Authorization; Class I devices do not. The review target is 30 calendar days from the start of screening. It is a target, not a default: there is no automatic authorization. Screening deficiencies must be fixed within 15 calendar days. If Health Canada asks for more information after review, the applicant has 60 days to answer and a new 30-day review starts. The manufacturer or importer applies. For Class III and IV devices, the Letter of Authorization can be issued before REB approval, as long as at least one qualified investigator is named; REB approval must reach Health Canada before the study starts. ITA applications carry no fee, and pre-ITA meetings are available (ITA guidance).

Practical points. Drug labels must carry the required information in English and French, and device labels need the investigational statements in both languages. The CTA must be attested by a senior medical or scientific officer residing in Canada. Our Canada page compares Canada and Latin America for first-in-human device trials.

Latin America: regulators and review order

Latin America is not one pathway. The order of ethics and regulator review is the biggest difference between countries. These are the published clocks; our site activation guide has the full country notes and sources.

Country Regulator Order Published clock
Panama MINSA; DNFD for medicines and health products Ethics and ministry in parallel Ethics up to 20 business days (10 expedited; 30 in total if the full committee reviews); DNFD 15 business days (Executive Decree 21 of 2026)
El Salvador SRS with the national ethics committee (CNEIS) One submission, parallel review (bioaccess® experience) No published clock; about 47 to 85 days to approval (bioaccess® experience)
Costa Rica CONIS Accredited ethics committee first, then CONIS registration CONIS acknowledges a complete registration within 5 business days; technical report within 10 business days
Brazil ANVISA Can be submitted in parallel; drug trials start after both approve ANVISA 90 business days for drug dossiers (RDC 945/2024); ethics 10 working days to check plus 30 days (Law 14,874)
Colombia INVIMA Ethics first, then INVIMA First INVIMA response within 60 business days for drug protocols (INVIMA guide GU039)
Mexico COFEPRIS Institutional committees first, then COFEPRIS 30 business days under the health research regulation (COFEPRIS guidance states 30 calendar days; confirm with us)
Argentina ANMAT Confirm with us Drug studies: 20 + 10 or 35 + 10 business days of technical and administrative review (Disposition 7516/2025)
Chile ISP Ethics report and ISP authorization for drug trials 45-day term, average evaluation 28 business days, reported by InvestChile
Ecuador ARCSA Ethics committee (CEISH) first, then ARCSA Document check in 7 days, then up to 60 days of technical review (extendable by 30)
Peru INS Ethics first, then INS Up to 30 working days

bioaccess® runs first-in-human studies in Colombia now.

In our recent plans, the quickest-review countries reached first patient about 8 to 9 months from a protocol synopsis, or about 4.5 to 6 months from a final protocol (bioaccess® experience). Ethics committee calendars and turnaround are practice, not law, and they vary by committee.

Will FDA accept data from outside the US?

Yes, when the study is designed and run for it. It is never automatic.

  • Drugs. FDA accepts a well-designed, well-conducted foreign study not run under an IND if it followed good clinical practice, including independent ethics committee review and informed consent, and FDA can validate the data through an onsite inspection if needed. The sponsor describes the steps taken to meet GCP (21 CFR 312.120). Approval based only on foreign data is governed separately (21 CFR 314.106).
  • Devices. For investigations that began on or after 21 February 2019, FDA accepts data from outside the US to support an IDE, 510(k), De Novo or PMA if the investigation is well designed and conducted, a GCP statement and the supporting information are provided, and FDA can validate the data (21 CFR 812.28). FDA notes that an IDE is not needed for a study conducted entirely at foreign sites, but FDA decides whether to accept the data (FDA).
  • Canada and Latin America are treated the same way. For FDA, both are foreign data. What matters is how the study was run, not the country.

Design rules that protect acceptance: follow ISO 14155 for devices and ICH GCP for drugs, use an independent ethics committee, keep source documents and device accountability inspection-ready, and show FDA your plan in a pre-submission meeting before the study starts. More detail: Panama and El Salvador data for an FDA IDE, 510(k) or De Novo.

Decision guide: which region fits your program

If your priority is… Consider Why
Iterating the device with FDA from the first case United States (EFS) FDA’s EFS Program is built for interactive review and fast design changes
US investigators who will run the pivotal study United States Early experience stays with US sites
A 30-day default drug review Canada 30-day CTA default, separate REB review
A device authorization that does not wait for ethics approval Canada Class III and IV ITA letters can issue before REB approval
A simplified export from the US Canada Tier-one country for FDA device export; listed country in 21 CFR 312.110(b) for drugs
Short review where ethics and regulator run in parallel Latin America (for example Panama; El Salvador (bioaccess® experience)) Parallel ethics and regulator review
Patient access and enrollment throughput Latin America Depends on the indication and the site; confirm with feasibility
Lower study cost Compare study-specific budgets in each region In our studies Latin American site costs have been lower than US costs (bioaccess® experience); see our line-by-line budget guide
Data that must support an FDA submission Any region In the US, run under the IND or IDE; outside the US, design for 312.120 or 812.28 from day one

Hybrid plans

Common sequences in our practice:

  1. Latin America first-in-human, then a US EFS or feasibility study. First human data before the US study; FDA sees the plan in a pre-submission.
  2. A US EFS with a parallel cohort in Canada or Latin America. US FDA interaction plus enrollment from other sites under one protocol.
  3. Canada for a drug phase 1, then Latin American and US sites for phase 2.

For cardiovascular devices, our sister organization Amavita Research runs a site in Miami, so one team can coordinate a US arm and a Latin American arm. See also US vs Latin America for first-in-human.

Questions to answer before you choose

  • Which FDA submission will this study support, and has FDA seen the plan?
  • Is the product used in the study identical to the one you will file, or do you need a documented comparison?
  • Who is the sponsor of record in each country, and who is the importer of record?
  • Which ethics committees review, how often do they meet, and in what language do they want the file?
  • Can the sites’ source documents and accountability logs pass an FDA inspection?
  • Do the sites see enough of your patients, and can they keep them through follow-up?
  • What is the export route from the US for your product?

Glossary

  • IND: Investigational New Drug application to FDA.
  • IDE: Investigational Device Exemption from FDA, for significant-risk device studies.
  • EFS: early feasibility study; a small, early device study, often first-in-human.
  • Q-Submission (Pre-Sub): a request for FDA feedback before a submission.
  • CTA: Clinical Trial Application to Health Canada (drugs).
  • NOL: No Objection Letter from Health Canada.
  • ITA: Investigational Testing Authorization from Health Canada (devices).
  • REB / IRB / ethics committee: the independent committee that reviews the study for participant protection.
  • GCP: good clinical practice (ICH E6 for drugs, ISO 14155 for devices).
  • Tier-one country: FDA’s short list of countries with simplified export of investigational devices; a similar country list applies to drugs in 21 CFR 312.110(b). No Latin American country is on either list.

Frequently asked questions

Is Canada’s CTA review really 7 days for phase 1?
Only for comparative bioavailability studies of pharmaceuticals in healthy adults that meet Health Canada’s criteria. A first-in-human study of a new drug follows the 30-day default review.

How long does FDA take to review an IND or IDE?
30 days from receipt. An IND takes effect after 30 days unless FDA places a clinical hold; an IDE study may begin after 30 days unless FDA objects, or earlier if FDA approves it by order.

Does Health Canada’s ITA authorize a device automatically after 30 days?
No. The 30 days is a review target, not a default. Health Canada issues a Letter of Authorization when the application meets the requirements.

Do I need an IDE to run a device study only in Latin America or Canada?
FDA says an IDE is not needed for a study conducted entirely at foreign sites. You still need the local approvals, and FDA evaluates the data under 812.28 when you submit it.

Will FDA accept first-in-human data from Latin America or Canada?
It can, when the study meets 21 CFR 312.120 (foreign drug studies not conducted under an IND) or 812.28 (devices): good clinical practice, independent ethics review, consent and data FDA can validate. Acceptance is decided per submission.

Which region is fastest to first patient?
It depends on the country and the study. FDA’s IND and IDE clocks are 30 days; Health Canada’s CTA has a 30-day default and the ITA a 30-calendar-day target from the start of screening, with no automatic authorization. In Latin America, published clocks range from about 4 weeks (Panama, parallel review) to several months where clocks are long or sequential. In our recent plans, the quickest-review Latin American countries reached first patient about 4.5 to 6 months from a final protocol (bioaccess® experience).

Which region is cheapest?
It depends on the study, the procedure and the sites, so compare study-specific budgets. In our studies, Latin American site costs have been lower than US costs (bioaccess® experience). See our sample budget.

Can I combine regions?
Yes. Some programs run a first-in-human cohort in one region and the next study in another, or a parallel cohort under one protocol. One regulatory strategy should cover all the regions.

What does Canada require that the US does not?
English and French label statements, and a CTA attestation by a senior medical or scientific officer residing in Canada.

Are these clocks calendar days or business days?
FDA and Health Canada clocks are calendar days. Most Latin American clocks are business days, so 30 business days is about 6 weeks on the calendar before holidays. The country table says which unit each clock uses.

Talk through your plan

Send us your synopsis and the FDA submission you are aiming for. We will tell you which regions and countries fit, and which don’t. Contact bioaccess®.

Related reading: Site activation timeline in Latin America · Importing investigational drugs and devices into Latin America · IDE vs IND · FDA Q-Submission · FDA IDE steps after you submit · Panama and El Salvador data for FDA · US vs Latin America for first-in-human · Canada vs Latin America for device trials · Clinical trial budget by country, line by line

Sources


← Back to Blog · Contact bioaccess®